FIELD: medicine.
SUBSTANCE: product containing a liquid aqueous preparation containing a prostaglandin derivative having at least one fluorine atom in a molecule, or a salt of the prostaglandin derivative at least one fluorine atom in a molecule, and the liquid aqueous preparation is kept in a polymer container sterilised by gas ethylene oxide. A method for preparing a product containing prostaglandin with inhibited reduction of the prostaglandin concentration.
EFFECT: reduction of the prostaglandin concentration is effectively inhibited in the product.
10 cl, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROSTAGLANDIN F2α DERIVATE INCLUDING PRODUCT | 2005 |
|
RU2391983C2 |
| PROTECTIVE MEDICIATION FOR RETINA NEURON WHICH CONTAINS AS ACTIVE COMPONETS PROSTAGLANDIN F2α DERIVATIVE | 2006 |
|
RU2414904C2 |
| AGENT PROMOTING HAIR GROWTH CONTAINING 15, 15-DIFLUOROPROSTAGLAN F DERIVATIVE AS ACTIVE INGREDIENT | 2009 |
|
RU2504380C2 |
| STORAGE OF STABLE PREPARATION OF PROSTAGLANDIN | 2010 |
|
RU2482851C2 |
| METHOD AND COMPOSITION FOR TREATING MACULAR DEGENERATION | 2010 |
|
RU2548762C2 |
| METHOD FOR PRODUCING 9-FLUORINE-PROSTAN DERIVATIVES OR THEIR SALTS WITH PHYSIOLOGICALLY ACCEPTABLE BASES | 0 |
|
SU1301308A3 |
| PHARMACEUTICAL COMPOSITION OF TAFLUPROST | 2021 |
|
RU2761625C2 |
| METHOD AND COMPOSITION FOR TREATING DISEASES OF PERIPHERAL VESSELS | 2006 |
|
RU2481841C2 |
| INTRAOCULAR SYSTEMS OF SUSTAINED-RELEASE DRUG DELIVERY AND METHOD OF TREATING OPHTHALMIC DISEASES | 2010 |
|
RU2532333C2 |
| METHOD OF TREATING ELEVATED INTRAOCULAR PRESSURE USING INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEM | 2014 |
|
RU2664686C2 |
